Clinical Trial Update: Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating anti-PD-1 combined with lenalidomide and azacitidine in relapsed/refractory peripheral T-cell lymphoma is ongoing but with a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Anti-PD-1
• Lenalidomide (lenalidomide)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Relapsed/Refractory Peripheral T-cell Lymphoma | Phase 2 | Status: UNKNOWN